COMMUNIQUÉS West-GlobeNewswire

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
11/06/2025
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug- [...]
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
11/06/2025
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today [...]
Precision Neuroscience Expands Leadership Team With Key Hires From Meta and FDA
11/06/2025
Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director of Medical Affairs NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leading [...]
Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program
11/06/2025
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that Ms. Jennifer [...]
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
11/06/2025
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to $1.5 [...]
Lisata Therapeutics to Present at the 2025 BIO International Convention
11/06/2025
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
Veru to Participate in the Virtual BTIG Obesity Health Forum
11/06/2025
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
GraceMed announces appointment of Dan Pawliw as Chief Executive Officer
11/06/2025
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- GraceMed, a leading consolidator in the plastic surgery, dermatology, and medical aesthetics industry, is pleased to announce the appointment of Dan Pawliw as its new Chief [...]
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
11/06/2025
SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA [...]
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
11/06/2025
Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos’ business model [...]
OKYO Pharma to Present at the Bio International Convention
11/06/2025
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a [...]
Artelo Biosciences Announces Reverse Stock Split
11/06/2025
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025 SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company [...]
IntelGenx Announces Rebranding to Nualtis, Signaling Strategic Evolution and Renewed Vision
11/06/2025
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- IntelGenx, a leader in oral thin film drug delivery, today announced its official rebrand to Nualtis, marking a pivotal step in the company’s transformation and long-term [...]
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research
11/06/2025
$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- [...]
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
11/06/2025
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a [...]
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
11/06/2025
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated therapeutics to [...]
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting [...]
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
11/06/2025
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company [...]
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated 2022, supporting [...]

Pages